ING Group’s Celldex Therapeutics CLDX Stock Holding History

ING Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-2,667	Closed	-$968K	–	695
2013 Q4	$968K	Buy	+2,667	New	+$1.03M	﹤0.01%	558

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ING Group's CLDX Position: Q1 2014 in Review

ING Group sold out of Celldex Therapeutics (CLDX) in Q1 2014, closing a stake of 2,667 shares — an estimated $968K sold.

ING Group first reported a position in CLDX in Q4 2013 and held it in 1 quarter. The position peaked at $968K in Q4 2013. 157 funds tracked by Wall St. Rank hold CLDX as of Q1 2014.

ING Group reported no remaining Celldex Therapeutics position as of Q1 2014 after selling out during the quarter.
ING Group sold 2,667 Celldex Therapeutics shares in Q1 2014, an estimated $968K.
ING Group first reported a position in Celldex Therapeutics in Q4 2013 and held it in 1 quarter.
ING Group's Celldex Therapeutics position peaked at $968K in Q4 2013.
157 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2014.

Based on ING Group's 13F filing for Q1 2014, filed 14 May 2014.